Published in PLoS One on August 23, 2010
Legal but lethal: functional protein aggregation at the verge of toxicity. Front Cell Neurosci (2015) 0.81
Prion subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level disparity. Mol Neurodegener (2012) 0.80
Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality. J Virol (2013) 0.78
Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake. J Virol (2015) 0.78
Sulfated glycosaminoglycans in protein aggregation diseases. Glycoconj J (2017) 0.77
The prion protein preference of sporadic Creutzfeldt-Jakob disease subtypes. J Biol Chem (2012) 0.75
Heparan Sulfate and Heparin Promote Faithful Prion Replication in Vitro by Binding to Normal and Abnormal Prion Proteins in Protein Misfolding Cyclic Amplification. J Biol Chem (2016) 0.75
Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Synthetic mammalian prions. Science (2004) 7.35
In vitro generation of infectious scrapie prions. Cell (2005) 6.86
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J (1996) 6.66
Generating a prion with bacterially expressed recombinant prion protein. Science (2010) 6.26
Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature (2001) 6.20
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A (2007) 5.94
RNA molecules stimulate prion protein conversion. Nature (2003) 4.06
Chlorate--a potent inhibitor of protein sulfation in intact cells. Biochem Biophys Res Commun (1986) 2.57
Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem (2010) 2.57
Prions and their partners in crime. Nature (2006) 2.55
Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol (2007) 2.31
Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem (2005) 2.29
Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc Natl Acad Sci U S A (2001) 2.16
Prion protein NMR structure and familial human spongiform encephalopathies. Proc Natl Acad Sci U S A (1998) 2.02
Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol (1979) 2.01
Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol (2004) 1.97
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry (2010) 1.68
Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol (2008) 1.63
On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein. Biochemistry (2001) 1.53
Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem (1995) 1.51
Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry (2003) 1.45
Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem (1998) 1.43
Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem (1999) 1.42
Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem (2002) 1.41
The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1. J Biol Chem (2001) 1.38
Binding of prion protein to lipid membranes and implications for prion conversion. J Mol Biol (2002) 1.35
Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem (2002) 1.35
Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem (2003) 1.34
Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem (2005) 1.32
Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest (1990) 1.32
Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol (1989) 1.26
Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol (1993) 1.26
A cell line infectible by prion strains from different species. J Gen Virol (2008) 1.21
Mutant and infectious prion proteins display common biochemical properties in cultured cells. J Biol Chem (1996) 1.20
Transmissible spongiform encephalopathies. Lancet (2004) 1.18
PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem (2005) 1.17
Small, highly structured RNAs participate in the conversion of human recombinant PrP(Sen) to PrP(Res) in vitro. J Mol Biol (2003) 1.17
The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J Mol Biol (2001) 1.16
In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry (2003) 1.15
DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol (2002) 1.11
Binding of prion proteins to lipid membranes. Biochem Biophys Res Commun (2004) 1.09
Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent. J Mol Biol (2004) 1.09
Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Sci (2006) 1.07
Mouse-adapted sporadic human Creutzfeldt-Jakob disease prions propagate in cell culture. Int J Biochem Cell Biol (2008) 1.06
Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res Bull (2005) 1.03
Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc Natl Acad Sci U S A (2007) 1.02
PrPc does not mediate internalization of PrPSc but is required at an early stage for de novo prion infection of Rov cells. J Virol (2007) 1.01
Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol (2002) 1.00
Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry (2007) 0.95
Aggregation and fibrillization of prions in lipid membranes. Biochem Soc Symp (2005) 0.95
A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol (2003) 0.93
PrPC has nucleic acid chaperoning properties similar to the nucleocapsid protein of HIV-1. C R Biol (2002) 0.92
Ionic strength and transition metals control PrPSc protease resistance and conversion-inducing activity. J Biol Chem (2004) 0.91
Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. J Mol Biol (2009) 0.91
Enzymatic detergent treatment protocol that reduces protease-resistant prion protein load and infectivity from surgical-steel monofilaments contaminated with a human-derived prion strain. J Gen Virol (2007) 0.89
Unifying electrostatic mechanism for phosphates and sulfates in cell signaling. J Recept Signal Transduct Res (2007) 0.86
Familial prion disease mutation alters the secondary structure of recombinant mouse prion protein: implications for the mechanism of prion formation. Biochemistry (1999) 0.85
Some biological characters of cell lines derived from normal rabbit kidney. J Pathol Bacteriol (1968) 0.83
A simplified recipe for prions. Proc Natl Acad Sci U S A (2007) 0.82
Unifying electrostatic mechanism for receptor-ligand activity. J Recept Signal Transduct Res (2007) 0.81
Unifying electrostatic mechanism for metal cations in receptors and cell signaling. J Recept Signal Transduct Res (2008) 0.79
A single amino acid alteration in murine PrP dramatically alters TSE incubation time. Arch Virol Suppl (2000) 0.78
Glycosaminoglycan analysis in brain stems from animals infected with the bovine spongiform encephalopathy agent. Arch Biochem Biophys (1999) 0.78
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics (2004) 4.09
Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med (2011) 3.95
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J (2002) 2.98
Validation of a GIS facilities database: quantification and implications of error. Ann Epidemiol (2008) 2.84
Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science (2004) 2.82
Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles. Cell (2013) 2.76
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res (2002) 2.52
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res (2012) 2.18
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Updated Creutzfeldt-Jakob disease infection control guidelines: sifting facts from fiction. Med J Aust (2013) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet (2006) 1.97
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med (2006) 1.72
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res (2009) 1.64
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem (2004) 1.63
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol (2009) 1.62
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics (2014) 1.53
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J (2008) 1.52
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51
Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J Neurosci (2005) 1.51
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery. Ann Thorac Surg (2009) 1.50
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49
Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2014) 1.48
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol (2002) 1.46
MYRF is a membrane-associated transcription factor that autoproteolytically cleaves to directly activate myelin genes. PLoS Biol (2013) 1.45
Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself (2010) 1.45
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
Molecular and clinical classification of human prion disease. Br Med Bull (2003) 1.45
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics (2014) 1.44
Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain (2011) 1.39
Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? Med J Aust (2010) 1.39
Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem (2003) 1.38
Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A (2008) 1.37
Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet Immunol Immunopathol (2008) 1.36
Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol (2007) 1.36
Major surface protein LipL32 is not required for either acute or chronic infection with Leptospira interrogans. Infect Immun (2008) 1.35
The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem (2009) 1.32
Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol (2004) 1.32
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology (2012) 1.31
The role of metallobiology and amyloid-β peptides in Alzheimer's disease. J Neurochem (2011) 1.31
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain (2013) 1.31
Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem (2006) 1.29
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A (2009) 1.29
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J (2004) 1.29
Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem (2010) 1.28
Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem (2002) 1.26
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol (2006) 1.23
Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain (2010) 1.22
Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc (2009) 1.22
ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem (2008) 1.20